| __timestamp | Rhythm Pharmaceuticals, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1213000 | 381287000 |
| Thursday, January 1, 2015 | 3425000 | 452612000 |
| Friday, January 1, 2016 | 6311000 | 316800000 |
| Sunday, January 1, 2017 | 9518000 | 330100000 |
| Monday, January 1, 2018 | 28080000 | 265800000 |
| Tuesday, January 1, 2019 | 36550000 | 336200000 |
| Wednesday, January 1, 2020 | 46125000 | 423900000 |
| Friday, January 1, 2021 | 68486000 | 467000000 |
| Saturday, January 1, 2022 | 92032000 | 487000000 |
| Sunday, January 1, 2023 | 117532000 | 477100000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. This analysis compares the SG&A expenses of United Therapeutics Corporation and Rhythm Pharmaceuticals, Inc. from 2014 to 2023. Over this period, United Therapeutics consistently reported higher SG&A expenses, peaking at approximately $487 million in 2022. In contrast, Rhythm Pharmaceuticals saw a dramatic increase, with expenses rising from just over $1 million in 2014 to nearly $118 million by 2023, marking a staggering growth of over 9,600%. This trend highlights the aggressive expansion and scaling efforts by Rhythm Pharmaceuticals. Meanwhile, United Therapeutics' expenses remained relatively stable, reflecting a mature operational strategy. Understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Verona Pharma plc
United Therapeutics Corporation vs Ultragenyx Pharmaceutical Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Geron Corporation
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Rhythm Pharmaceuticals, Inc. and MiMedx Group, Inc.